Synopsis

Source of validity: Scientific
Rating (out of 5): 2

β-Nicotinamide mononucleotide (NMN) has recently attracted interest as a potential supportive agent in the treatment of radiation sickness, primarily based on preclinical scientific research. NMN is a key intermediate in NAD⁺ biosynthesis, and NAD⁺ is essential for DNA repair, cellular metabolism, and cell survival—processes that are severely compromised following exposure to ionizing radiation. Several animal studies have demonstrated that administration of NMN can replenish NAD⁺ levels, enhance DNA repair capacity, and improve survival rates in models of acute radiation exposure. For example, a 2019 study by Fang et al. in Science showed that NMN administration in mice after total body irradiation reduced radiation-induced hematopoietic stem cell exhaustion and improved overall survival, likely through promoting DNA repair and stem cell function. However, clinical evidence in humans is currently lacking, and no regulatory approvals exist for NMN as a treatment or supportive therapy for radiation sickness. Therefore, while there is a scientific rationale and some promising preclinical evidence, the overall quality and quantity of evidence are still limited (rated 2/5). Further clinical trials are necessary to establish the efficacy and safety of NMN in the context of radiation sickness in humans.

More about β-nicotinamide mononucleotide (NMN)
More about Radiation Sickness

Other ingredients used for Radiation Sickness

Other health conditions supported by β-nicotinamide mononucleotide (NMN)

Products containing β-nicotinamide mononucleotide (NMN)

Designs For Health Liposomal NMN Synergy 1.7 fl oz (50 ml) liquid. Nonreturnable item.